MetaCap

Aclaris Therapeutics (ACRS) vs Geron (GERN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aclaris Therapeutics (ACRS) has outperformed Geron (GERN) over the past year, gaining 37.1% versus a loss of 22.3%. Over five years, GERN leads with a -40.8% price change compared with -72.7% for ACRS. Geron is the larger company by market cap ($560.9 million vs $545.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRS+37.05%GERN-22.26%
+169%+69%-31%
Nov 21, 20251 yearNov 20, 2026
ACRS-75.05%GERN-43.46%
+232%+61%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRS versus GERN key metrics
MetricACRSGERN
Share price$3.44$0.8707
Market cap$545.63M$560.94M
1-day change-1.71%-4.63%
YTD return+14.29%-34.04%
1-year return+37.05%-22.26%
5-year return-72.74%-40.77%
Forward P/E—9.67
EPS (TTM)$-0.59$-0.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.83M—
Revenue growth (YoY)-58.19%—
Net income (latest FY)$-64.92M$-83.50M
Gross margin73.28%—
Operating margin-975.91%—
Net margin-829.58%—
52-week high$6.60$2.01
52-week low$2.46$0.84
Distance from 52-week high-47.88%-56.68%
Analyst consensusstrong_buybuy
Avg. price target upside+205.23%+301.98%
Average volume3.07M13.05M
Shares outstanding158.61M644.24M
Employees69258
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ACRS has outperformed GERN by 59.3 percentage points over the past year.

About Aclaris Therapeutics

ACRS stock →

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Geron

GERN stock →

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.

Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees

ACRS vs GERN FAQ

Which is bigger, Aclaris Therapeutics or Geron?

Geron (GERN) is larger, with a market capitalization of $560.94M compared with $545.63M for Aclaris Therapeutics (ACRS).

Which stock has performed better over the past year, ACRS or GERN?

ACRS returned +37.05% over the past 12 months, compared with -22.26% for GERN (price return, excluding dividends). Past performance does not predict future results.

Are Aclaris Therapeutics and Geron in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons